Bridgeway Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Bridgeway Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-72,600	Closed	-$37.8K	–	1239
2024 Q4	$37.8K	Sell	72,600 -108,477	-60%	-$265K	﹤0.01%	1165
2024 Q3	$587K	Hold	181,077	–	–	0.01%	825
2024 Q2	$543K	Sell	181,077 -14,700	-8%	-$53.2K	0.01%	839
2024 Q1	$910K	Buy	195,777 +25,700	+15%	+$124K	0.02%	764
2023 Q4	$704K	Buy	170,077 +68,075	+67%	+$202K	0.02%	849
2023 Q3	$306K	Buy	102,002 +24,302	+31%	+$72.2K	0.01%	1005
2023 Q2	$191K	Buy	77,700 +45,000	+138%	+$124K	﹤0.01%	1144
2023 Q1	$73.9K	Buy	+32,700	New	+$113K	﹤0.01%	1275

Other funds holding RLMD

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Bridgeway Capital Management's RLMD Position: Q1 2025 in Review

Bridgeway Capital Management sold out of Relmada Therapeutics (RLMD) in Q1 2025, closing a stake of 72,600 shares — an estimated $37.8K sold.

Bridgeway Capital Management first reported a position in RLMD in Q1 2023 and held it in 8 quarters. The position peaked at $910K in Q1 2024. 44 funds tracked by Wall St. Rank hold RLMD as of Q1 2025.

Bridgeway Capital Management reported no remaining Relmada Therapeutics position as of Q1 2025 after selling out during the quarter.
Bridgeway Capital Management sold 72,600 Relmada Therapeutics shares in Q1 2025, an estimated $37.8K.
Bridgeway Capital Management first reported a position in Relmada Therapeutics in Q1 2023 and held it in 8 quarters.
Bridgeway Capital Management's Relmada Therapeutics position peaked at $910K in Q1 2024.
44 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2025.

Based on Bridgeway Capital Management's 13F filing for Q1 2025, filed 15 May 2025.